TY - JOUR
T1 - Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients
AU - Santini, Daniele
AU - Vincenzi, Bruno
AU - Adamo, Vincenzo
AU - Addeo, Raffaele
AU - Fusco, Vittorio
AU - Russo, Antonio
AU - Montemurro, Filippo
AU - Roato, Ilaria
AU - Redana, Stefania
AU - Lanzetta, Gaetano
AU - Satolli, Maria Antonietta
AU - Berruti, Alfredo
AU - Leoni, Valentina
AU - Galluzzo, Sara
AU - Antimi, Mauro
AU - Ferraro, Giuseppa
AU - Del Salvatore, Prete
AU - Valerio, Maria Rosaria
AU - Marra, Monica
AU - Caraglia, Michele
AU - Tonini, Giuseppe
PY - 2011/6
Y1 - 2011/6
N2 - Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N- nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) treated with trastuzumab-based therapy as first line combination for metastatic disease were considered eligible. For all included patients data on smoking habit were detectable from medical records. We retrospectively analysed the smoking habits of 248 MBC patients and correlated these habits with activity and efficacy of trastuzumab-based therapy. No statistically significant difference in terms of response rate (RR), time to progression (TTP) and overall survival (OS) was identified between smokers (former plus active smokers) and never smokers. Moreover, no statistically significant difference in terms of RR, TTP and OS was identified either comparing active smokers and former smokers. Moreover, we did not observed any significant statistical difference in terms of TTP and OS between smokers ≥10 cigarettes/day and ≤10 cigarettes/day. This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/neu positive breast cancer patients.
AB - Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N- nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) treated with trastuzumab-based therapy as first line combination for metastatic disease were considered eligible. For all included patients data on smoking habit were detectable from medical records. We retrospectively analysed the smoking habits of 248 MBC patients and correlated these habits with activity and efficacy of trastuzumab-based therapy. No statistically significant difference in terms of response rate (RR), time to progression (TTP) and overall survival (OS) was identified between smokers (former plus active smokers) and never smokers. Moreover, no statistically significant difference in terms of RR, TTP and OS was identified either comparing active smokers and former smokers. Moreover, we did not observed any significant statistical difference in terms of TTP and OS between smokers ≥10 cigarettes/day and ≤10 cigarettes/day. This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/neu positive breast cancer patients.
KW - Metastatic breast cancer
KW - Smoking
KW - Trastuzumab
UR - http://www.scopus.com/inward/record.url?scp=79954539962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954539962&partnerID=8YFLogxK
U2 - 10.3892/or.2011.1235
DO - 10.3892/or.2011.1235
M3 - Article
C2 - 21455582
AN - SCOPUS:79954539962
VL - 25
SP - 1545
EP - 1548
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 6
ER -